Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03089970 · ClinicalTrials.gov registry record
Using Breath Metabolites to Determine Specific Virus Infection in Asthmatic Patients
A clinical trial, sponsored by University of California, Davis.
- Completed
- Registry status
- 19
- Enrollment target
NCT03089970: Completed study, sponsored by University of California, Davis.
NCT03089970 is a clinical trial that has completed, run by University of California, Davis. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03089970 has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
Respiratory virus infections cause a majority of asthma exacerbations in the fall to spring months. Current diagnostic platforms for respiratory viruses have limitations including cost, availability, and invasiveness. The use of noninvasive breath collection to analyze breath metabolites may be used to differentiate virus-infected asthmatics from other causes of acute asthma exacerbations.
Primary Outcome
Metabolites from breath will be identified and quantified using gas chromatography-mass spectrometry; these will be compared between groups. Specific breath metabolites include isoprostane, linear and branched alkanes (C6-C9), alcohols, and thiol-containing moieties. However, we will also measure metabolites in an un-targeted manner.
Interventions
- DIAGNOSTIC_TEST Exhaled breath condensate collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2020-09-01 |
What the finished NCT03089970 record still lists
NCT03089970 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Exhaled breath condensate collection is the first listed.
NCT03089970 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03089970 about?
NCT03089970 is a clinical study titled "Using Breath Metabolites to Determine Specific Virus Infection in Asthmatic Patients". Respiratory virus infections cause a majority of asthma exacerbations in the fall to spring months. Current diagnostic platforms for respiratory viruses have limitations including cost, availability, and invasiveness. The use of noninvasive breath collection to analyze breath metabolites may be used...
What is the current status of trial NCT03089970?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2017-02-01. Estimated completion is 2020-09-01.
What interventions are being tested in trial NCT03089970?
The interventions under investigation include: Exhaled breath condensate collection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03089970?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI